JP6284471B2 - インスリン抵抗性のための改善されたペプチドの調合薬 - Google Patents

インスリン抵抗性のための改善されたペプチドの調合薬 Download PDF

Info

Publication number
JP6284471B2
JP6284471B2 JP2014511554A JP2014511554A JP6284471B2 JP 6284471 B2 JP6284471 B2 JP 6284471B2 JP 2014511554 A JP2014511554 A JP 2014511554A JP 2014511554 A JP2014511554 A JP 2014511554A JP 6284471 B2 JP6284471 B2 JP 6284471B2
Authority
JP
Japan
Prior art keywords
absent
peptide
aib
ac4c
ac5c
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014511554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516037A (ja
JP2014516037A5 (enExample
Inventor
ネスター，ジョン，ジェイ．
Original Assignee
メデリス ダイアビーティーズ，エルエルシー
メデリス ダイアビーティーズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メデリス ダイアビーティーズ，エルエルシー, メデリス ダイアビーティーズ，エルエルシー filed Critical メデリス ダイアビーティーズ，エルエルシー
Publication of JP2014516037A publication Critical patent/JP2014516037A/ja
Publication of JP2014516037A5 publication Critical patent/JP2014516037A5/ja
Application granted granted Critical
Publication of JP6284471B2 publication Critical patent/JP6284471B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
JP2014511554A 2011-05-18 2012-05-17 インスリン抵抗性のための改善されたペプチドの調合薬 Active JP6284471B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161487640P 2011-05-18 2011-05-18
US61/487,640 2011-05-18
US201161543716P 2011-10-05 2011-10-05
US61/543,716 2011-10-05
PCT/US2012/038434 WO2012158965A2 (en) 2011-05-18 2012-05-17 Improved peptide pharmaceuticals for insulin resistance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017028560A Division JP6684396B2 (ja) 2011-05-18 2017-02-19 インスリン抵抗性のための改善されたペプチドの調合薬

Publications (3)

Publication Number Publication Date
JP2014516037A JP2014516037A (ja) 2014-07-07
JP2014516037A5 JP2014516037A5 (enExample) 2015-07-09
JP6284471B2 true JP6284471B2 (ja) 2018-02-28

Family

ID=47177642

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014511554A Active JP6284471B2 (ja) 2011-05-18 2012-05-17 インスリン抵抗性のための改善されたペプチドの調合薬
JP2017028560A Active JP6684396B2 (ja) 2011-05-18 2017-02-19 インスリン抵抗性のための改善されたペプチドの調合薬
JP2019192289A Active JP7015610B2 (ja) 2011-05-18 2019-10-21 インスリン抵抗性のための改善されたペプチドの調合薬
JP2022005872A Active JP7389150B2 (ja) 2011-05-18 2022-01-18 インスリン抵抗性のための改善されたペプチドの調合薬

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017028560A Active JP6684396B2 (ja) 2011-05-18 2017-02-19 インスリン抵抗性のための改善されたペプチドの調合薬
JP2019192289A Active JP7015610B2 (ja) 2011-05-18 2019-10-21 インスリン抵抗性のための改善されたペプチドの調合薬
JP2022005872A Active JP7389150B2 (ja) 2011-05-18 2022-01-18 インスリン抵抗性のための改善されたペプチドの調合薬

Country Status (13)

Country Link
US (1) US10471127B2 (enExample)
EP (1) EP2710031B9 (enExample)
JP (4) JP6284471B2 (enExample)
KR (5) KR102011924B1 (enExample)
CN (2) CN111701028A (enExample)
AU (1) AU2012255119B2 (enExample)
BR (1) BR112013029409B1 (enExample)
CA (2) CA3134906A1 (enExample)
DK (1) DK2710031T3 (enExample)
IL (1) IL229373B (enExample)
MX (1) MX344219B (enExample)
RU (1) RU2602801C2 (enExample)
WO (1) WO2012158965A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501204A (ja) * 2012-11-20 2016-01-18 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101171262B (zh) 2005-05-04 2012-06-27 西兰制药公司 胰高血糖素样肽-2(glp-2)类似物
NZ576260A (en) 2006-11-08 2012-04-27 Zealand Pharma As GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
CN108892709A (zh) 2011-05-18 2018-11-27 欧莫德里斯制药公司 改良的肽药物
US10471127B2 (en) * 2011-05-18 2019-11-12 Mederis Diabetes, Llc Peptide pharmaceuticals for insulin resistance
WO2013041678A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP4047023A1 (en) * 2012-11-20 2022-08-24 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
RU2683039C2 (ru) 2013-04-18 2019-03-26 Ново Нордиск А/С Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
CN117180445A (zh) * 2014-05-28 2023-12-08 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR103322A1 (es) 2014-12-30 2017-05-03 Hanmi Pharm Ind Co Ltd Derivados de glucagón con estabilidad mejorada
US11505648B2 (en) * 2015-04-21 2022-11-22 Ran Biotechnologies, Inc. Fluorinated surfactants
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
CR20180034A (es) 2015-06-30 2018-04-16 Hanmi Pharm Ind Co Ltd Derivados de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
AU2016382394B2 (en) 2015-12-31 2019-07-04 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
PE20190355A1 (es) * 2016-06-29 2019-03-07 Hanmi Pharm Ind Co Ltd Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
CA3043151A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
EP4424362A3 (en) 2017-06-16 2024-11-27 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
CN108054388B (zh) * 2017-12-26 2020-02-21 吉林大学 以h6p2w18/l-3-(2-萘基)-丙氨酸复合水基黏合剂为电极涂层的化学电池
CN111818971A (zh) * 2018-01-03 2020-10-23 梅德瑞斯糖尿病有限责任公司 用于治疗nash和其他紊乱的改进的肽药物
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
CA3220005A1 (en) 2021-05-13 2022-11-17 Carmot Therapeutics Inc. Modulators of g-protein coupled receptors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
JPH1160598A (ja) 1997-08-15 1999-03-02 Asahi Glass Co Ltd オピオイド様ペプチド
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
RU2181729C1 (ru) 2000-09-20 2002-04-27 Калюжин Олег Витальевич Производные мурамовой кислоты
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
ITRM20040607A1 (it) 2004-12-15 2005-03-15 Biogen S R L Analoghi della dermorfina ad attivita' analgesica.
US7776819B2 (en) 2005-03-03 2010-08-17 The Board Of Trustees Of The University Of Illinois Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
JP2008539735A (ja) * 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法
WO2007002465A2 (en) 2005-06-23 2007-01-04 Rapid Pharmaceuticals, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2007060692A2 (en) 2005-11-24 2007-05-31 Brain N' Beyond Biotech Pvt. Ltd. Compositions for increasing bioavailability of peptides or proteins and method thereof
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20100041872A1 (en) * 2006-10-04 2010-02-18 Defrees Shawn Glycerol linked pegylated sugars and glycopeptides
PA8830501A1 (es) * 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CN108892709A (zh) * 2011-05-18 2018-11-27 欧莫德里斯制药公司 改良的肽药物
US10471127B2 (en) 2011-05-18 2019-11-12 Mederis Diabetes, Llc Peptide pharmaceuticals for insulin resistance
EP4047023A1 (en) 2012-11-20 2022-08-24 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
KR102365582B1 (ko) 2012-11-20 2022-02-18 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 약제
CN117180445A (zh) 2014-05-28 2023-12-08 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501204A (ja) * 2012-11-20 2016-01-18 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤

Also Published As

Publication number Publication date
US10471127B2 (en) 2019-11-12
EP2710031B1 (en) 2017-09-13
JP2020073481A (ja) 2020-05-14
DK2710031T3 (en) 2018-01-02
KR20140040164A (ko) 2014-04-02
RU2602801C2 (ru) 2016-11-20
AU2012255119A1 (en) 2013-12-05
AU2012255119B2 (en) 2017-04-20
KR20230023059A (ko) 2023-02-16
WO2012158965A2 (en) 2012-11-22
KR20210060653A (ko) 2021-05-26
CA3134906A1 (en) 2012-11-22
EP2710031B9 (en) 2018-02-28
BR112013029409A2 (pt) 2016-11-29
JP6684396B2 (ja) 2020-04-22
WO2012158965A3 (en) 2013-01-10
CA2836574C (en) 2021-11-30
JP2014516037A (ja) 2014-07-07
MX344219B (es) 2016-12-07
NZ617824A (en) 2016-03-31
BR112013029409B1 (pt) 2022-03-29
KR20190097299A (ko) 2019-08-20
IL229373A0 (en) 2014-01-30
JP2017171650A (ja) 2017-09-28
KR102011924B1 (ko) 2019-08-21
KR102497726B1 (ko) 2023-02-07
EP2710031A4 (en) 2014-10-15
CN103732617A (zh) 2014-04-16
KR102255479B1 (ko) 2021-05-24
CN111701028A (zh) 2020-09-25
KR20240110072A (ko) 2024-07-12
EP2710031A2 (en) 2014-03-26
JP2022064918A (ja) 2022-04-26
CA2836574A1 (en) 2012-11-22
US20140349928A1 (en) 2014-11-27
BR112013029409A8 (pt) 2018-01-30
IL229373B (en) 2018-08-30
JP7389150B2 (ja) 2023-11-29
JP7015610B2 (ja) 2022-02-15
MX2013013395A (es) 2014-02-27
RU2013154047A (ru) 2015-06-27

Similar Documents

Publication Publication Date Title
JP7389150B2 (ja) インスリン抵抗性のための改善されたペプチドの調合薬
US20240424062A1 (en) Peptide pharmaceuticals for insulin resistance
US20200289653A1 (en) Improved peptide pharmaceuticals for insulin resistance
US20250313604A1 (en) Peptide pharmaceuticals for insulin resistance
NZ617824B2 (en) Improved peptide pharmaceuticals for insulin resistance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160229

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170219

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180130

R150 Certificate of patent or registration of utility model

Ref document number: 6284471

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250